Replies to post #202974 on Biotech Values

[tmoney2555]

Thanks for the info Dew

[DewDiligence]

ABBV/ENTA obvious pattern—Viekira market share is much higher in populations that are predominantly GT1b (EU, Japan) than in populations that are predominantly GT1a (US).

[willyw]

Thank you for your post.

Japan looks much better than last quarter. I was wondering where it would be. Not bad.

I have the view that both Gilead and Abbvie are resisting price cutting measures since they have viable long term HCV programs. I'm not so sure Merck does; hence the deep discounts.

Bottom line, Abbvie sold less product world wide, but I am thinking that the royalty picture may be slightly better for ENTA than last quarters due to the better economics in Japan 45% versus 33% for Viekira.

Soon they will be dosing the once daily program, the expanded use to G-1b early stage cirrhotics.
They still excel with G-1b,
AND are a lot of G-1b's in the world.

[DewDiligence]

MRK 3Q16 Zepatier sales were $164M (+46% vs 2Q16, but somewhat below consensus expectations):

http://finance.yahoo.com/news/merck-announces-third-quarter-2016-104500399.html

[DewDiligence]

3Q16 Harvoni/Epclusa vs Viekira* vs Zepatier ($ M)

 
 Total  
 Harvoni/Epclusa 2500  82.2% 
 Viekira          378  12.4% 
 Zepatier         164   5.4% 
  
 US  
 Harvoni/Epclusa 1677  87.5% 
 Viekira           76   4.0% 
 Zepatier         164   8.6% 
  
 Ex-US  
 Harvoni/Epclusa  823  73.2% 
 Viekira          302  26.8%  
 Zepatier         n/a   n/a 

*Includes Viekirax/Technivie (2-DAA) brands.